Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11761789 | 0.90 | L3MBTL1 (0.41) | L3MBTL1MGLLMEN1KMT2ATDP1 | |
| SCHEMBL5257405 | 0.90 | L3MBTL1 (0.38) | L3MBTL1MGLLMEN1KMT2ATDP1 | |
| SCHEMBL18583119 | 0.83 | — | — | |
| SCHEMBL19881640 | 0.81 | MGLL (0.43) | L3MBTL1MGLLMEN1KMT2ATDP1 | |
| SCHEMBL27531894 | 0.75 | GBA2 (0.37) | — | |
| SCHEMBL22357261 | 0.75 | — | — | |
| SCHEMBL23507455 | 0.74 | MGLL (0.35) | MGLL | |
| SCHEMBL18701472 | 0.74 | MGLL (0.35) | MGLLTDP1TSHR | |
| SCHEMBL20072088 | 0.73 | MGLL (0.31) | MGLL | |
| SCHEMBL20072244 | 0.72 | MGLL (0.35) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874673-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-10039762-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180078553-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-22 | — | — | US | disclosed |
| US-9808459-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-13 | — | — | US | disclosed |
| WO-2010028051-A2 | SUBSTITUTED HETEROCYCLIC MERCAPTOSULFONAMIDE METALLOPROTEASE INHIBITORS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078553-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | L3MBTL1 4645/4885MGLL 1395/4885MEN1 3469/4885 |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | L3MBTL1 4645/4885MGLL 1395/4885MEN1 3469/4885 |
| US-10874673-B2 | Inhibitors of influenza viruses replication | ACE, IRF3, ACE2 | L3MBTL1 4645/4885MGLL 1395/4885MEN1 3469/4885 |
| US-10039762-B2 | Inhibitors of influenza viruses replication | ACE, IRF3, ACE2 | L3MBTL1 4645/4885MGLL 1395/4885MEN1 3469/4885 |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | L3MBTL1 4645/4885MGLL 1395/4885MEN1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.